About: Prognostic value of NT-proBNP in patients with severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognostic value of NT-proBNP in patients with severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prognostic value of NT-proBNP in patients with severe COVID-19
Creator	Gao, Lei Sun, Min He, Bin Cai, Guo-Qiang Cheng, Xiao-Cheng Jiang, Dan Lei, Peng Qin, Shu Wen, Xue-Song You, Lin-Na Tan, Xiao-Wei Zhang, Dong-Ying
Source	Medline; PMC
abstract	BACKGROUND: The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown. METHODS: The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records. RESULTS: The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death. CONCLUSION: NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19. TRIAL REGISTRATION: ClinicalTrials, NCT04292964. Registered 03 March 2020,
has issue date	2020-04-15(xsd:dateTime)
bibo:doi	10.1186/s12931-020-01352-w
bibo:pmid	32293449
has license	cc-by
sha1sum (hex)	c3cf02d2f1c97df0c6256a8287e7fee729359b42
schema:url	https://doi.org/10.1186/s12931-020-01352-w
resource representing a document's title	Prognostic value of NT-proBNP in patients with severe COVID-19
has PubMed Central identifier	PMC7156898
has PubMed identifier	32293449
schema:publication	Respir Res
resource representing a document's body	covid:c3cf02d2f1c97df0c6256a8287e7fee729359b42#body_text
is schema:about of	named entity 'Methods' named entity 'initially' named entity 'coronavirus disease 2019' named entity 'caused' named entity 'NT-proBNP' named entity 'SEVERE COVID-19' named entity 'EMERGENCY' named entity 'CONTINUOUS' named entity 'ENROLLED' named entity 'PREDICTED' named entity 'CONCERN' named entity 'INITIALLY' named entity 'SAMPLE' named entity 'natriuretic peptide' named entity 'primary' named entity 'Research' named entity 'COVID-19' named entity 'patients' named entity 'data' named entity 'COVID' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'primary outcome' named entity 'COVID-19' named entity 'inflammation' named entity 'COVID' named entity 'virus' named entity 'COVID' named entity '7.2' named entity 'myoglobin' named entity 'respiratory rate' named entity 'risk factor' named entity 'virus' named entity 'NT-proBNP' named entity 'cardiomyocytes' named entity 'CRP' named entity 'NT-proBNP' named entity 'regression analysis' named entity 'carboxypeptidase' named entity 'diastolic blood pressure' named entity 'physiological' named entity '95% CI' named entity 'patient record' named entity 'natriuretic peptide' named entity 'NT-proBNP' named entity 'COVID' named entity 'creatinine' named entity 'COVID-19' named entity 'pulmonary infection' named entity 'NT-proBNP' named entity 'WBC' named entity 'COVID' named entity 'clinical outcomes' named entity 'COVID' named entity 'therapeutic strategies' named entity 'MYO' named entity 'Spearman correlation' named entity 'pulse rate' named entity 'cardiovascular' named entity 'inadequate oxygen' named entity 'preexisting conditions' named entity 'heart failure' named entity 'Chicago' named entity 'CRP' named entity 'oxyhemoglobin' named entity 'procalcitonin' named entity 'oxygen' named entity 'creatinine' named entity 'CK-MB'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software